These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 22258251)

  • 1. Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1.
    Gallastegui E; Marshall B; Vidal D; Sanchez-Duffhues G; Collado JA; Alvarez-Fernández C; Luque N; Terme JM; Gatell JM; Sánchez-Palomino S; Muñoz E; Mestres J; Verdin E; Jordan A
    J Virol; 2012 Apr; 86(7):3795-808. PubMed ID: 22258251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.
    Yang HC; Xing S; Shan L; O'Connell K; Dinoso J; Shen A; Zhou Y; Shrum CK; Han Y; Liu JO; Zhang H; Margolick JB; Siliciano RF
    J Clin Invest; 2009 Nov; 119(11):3473-86. PubMed ID: 19805909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.
    Xing S; Bhat S; Shroff NS; Zhang H; Lopez JA; Margolick JB; Liu JO; Siliciano RF
    J Antimicrob Chemother; 2012 Feb; 67(2):398-403. PubMed ID: 22160146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.
    Spina CA; Anderson J; Archin NM; Bosque A; Chan J; Famiglietti M; Greene WC; Kashuba A; Lewin SR; Margolis DM; Mau M; Ruelas D; Saleh S; Shirakawa K; Siliciano RF; Singhania A; Soto PC; Terry VH; Verdin E; Woelk C; Wooden S; Xing S; Planelles V
    PLoS Pathog; 2013; 9(12):e1003834. PubMed ID: 24385908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
    Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation.
    Bosque A; Nilson KA; Macedo AB; Spivak AM; Archin NM; Van Wagoner RM; Martins LJ; Novis CL; Szaniawski MA; Ireland CM; Margolis DM; Price DH; Planelles V
    Cell Rep; 2017 Jan; 18(5):1324-1334. PubMed ID: 28147284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
    Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
    PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency.
    Lu P; Shen Y; Yang H; Wang Y; Jiang Z; Yang X; Zhong Y; Pan H; Xu J; Lu H; Zhu H
    Sci Rep; 2017 Nov; 7(1):16646. PubMed ID: 29192216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells.
    Shan L; Xing S; Yang HC; Zhang H; Margolick JB; Siliciano RF
    J Antimicrob Chemother; 2014 Jan; 69(1):28-33. PubMed ID: 23999005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.
    de Armas LR; Gavegnano C; Pallikkuth S; Rinaldi S; Pan L; Battivelli E; Verdin E; Younis RT; Pahwa R; Williams SL; Schinazi RF; Pahwa S
    Front Immunol; 2021; 12():720697. PubMed ID: 34531866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
    Rochat MA; Schlaepfer E; Speck RF
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
    Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of latency reversal agents in the cure of HIV: A review of current data.
    Bashiri K; Rezaei N; Nasi M; Cossarizza A
    Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.
    Xing S; Bullen CK; Shroff NS; Shan L; Yang HC; Manucci JL; Bhat S; Zhang H; Margolick JB; Quinn TC; Margolis DM; Siliciano JD; Siliciano RF
    J Virol; 2011 Jun; 85(12):6060-4. PubMed ID: 21471244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
    Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
    PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.